By Robb M. Stewart
ProQR Therapeutics has turned to a new chief financial officer and fresh chief medical officer to support the next phase of growth for the RNA therapies developer.
The Netherlands-based, Nasdaq-listed company said Monday it appointed Dennis Hom as finance chief and Cristina Lopez Lopez as chief medical officer to support the advancement of its Axiomer platform technology and pipeline of RNA editing programs as it enters the clinical stage.
Chief Financial Officer Jurriaan Dekkers and Chief Corporate Development Officer Rene Beukema will step down from their roles.
Hom most recently was CFO and head of corporate development at Sagimet Biosciences. Lopez most recently she served as global head of neurodegeneration at Johnson & Johnson.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
April 14, 2025 07:44 ET (11:44 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.